MINNEAPOLIS, Sept. 25, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2023 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized around four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment. Bio-Techne's EPIC values (Empowerment, Passion, Innovation and Collaboration) remain the backbone of our corporate culture and provide the foundation for our approach to continuously improving our corporate sustainability. The updated CSR is available in the Corporate and Social Responsibility section of Bio-Techne's website.

"I am proud of the progress the team continues to make building a sustainable, durable and growing business," said Chuck Kummeth, President and Chief Executive Officer of Bio-Techne. "Bio-Techne's commitment to its employees and surrounding communities, paired with a focus on innovation, governance and operational integrity, enables the team to grow the organization in a responsible manner and deliver the products necessary to develop and advance the next-generation of therapeutics, vaccines and diagnostics that improve global healthcare."

About Bio-Techne 
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2023 and has approximately 3,200 employees worldwide. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations


Cision View original content to download multimedia:

SOURCE Bio-Techne Corporation